Mrna

Moderna and Merck cancer vaccine cuts melanoma recurrence by 44% in late-stage trial

Moderna and Merck said their personalized mRNA cancer vaccine reduced the risk of melanoma recurrence or death by 44% when paired with Keytruda, compared with Keytruda alone, in a phase 3 trial…